id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-267856-t3ksa18w	Funk, Colin D.	A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes	2020-08-06		.txt	text/plain	4340	232	43	We offer a simple treatment paradigm using two generic drugs targeting the hyperinflammatory response that characterizes the turning point from mild to severe/critical COVID-19 by targeting leukotriene biosynthesis with zileuton (Zyflo(®) controlled release formulation) and antagonism of the cysteinyl leukotriene 1 receptor with montelukast (Singulair(®)). By targeting vascular permeability, immune modulating and general inflammation-dampening effects at the CysLT 1 level with montelukast (Dahleń et al., 1981; Maeba et al., 2005; Capra et al., 2007; Tahan et al., 2008; Khodir et al., 2014) and LT biosynthesis with the 5-lipoxygenase inhibitor zileuton, to block both arms of the LT pathway ( Figure 2 ) and remove ligands for another key receptor regulating vascular permeability, CysLT 2 (Moos et al., 2008) , as well as inflammatory cell recruitment and endothelial cell adhesion via BLT 1 receptor (Ford-Hutchinson et al., 1980; Tager et al., 2003; Taube et al., 2006; Sasaki and Yokomizo, 2019) , there is a sound scientific basis for alleviating disease progression from mild to severe-critical stages of COVID-19 (Figures 1 and 2) .	./cache/cord-267856-t3ksa18w.txt	./txt/cord-267856-t3ksa18w.txt